H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Collegium Pharmaceutical (NASDAQ:COLL) on Monday, setting a price target of $31, which is approximately 44.39% above the present share price of $21.47.
Livnat expects Collegium Pharmaceutical to post earnings per share (EPS) of -$0.07 for the second quarter of 2020.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Collegium Pharmaceutical, with an average price target of $34.2.
The analysts price targets range from a high of $43 to a low of $24.
In its latest earnings report, released on 12/31/2019, the company reported a quarterly revenue of $74.2 million and a net profit of -$2.37 million. The company's market cap is $736.55 million.
According to TipRanks.com, H.C. Wainwright analyst Oren Livnat is a 3-star analyst with an average return of 0.6% and a 43.9% success rate.
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.